Gerald E. Spotts

2.9k citations

46 papers · 2.5k · 1 hit paper · h-index 21

Impact in

Virology top 1%
- HIV Research and Treatment
Hematology top 1%
- Hemophilia Treatment and Research
- Platelet Disorders and Treatments
- Blood Coagulation and Thrombosis Mechanisms

Papers in

Hematology 29
- Hemophilia Treatment and Research 29
- Chronic Myeloid Leukemia Treatments 9
- Platelet Disorders and Treatments 9
- Blood Coagulation and Thrombosis Mechanisms 4
Virology 13
- HIV Research and Treatment 13

Co-authors: Bruce M. Ewenstein (21 shared papers)Victor S. Blanchette (17 shared papers)Kathelijn Fischer (13 shared papers)Frederick M. Hecht (13 shared papers)P Schroth (6 shared papers)M. Oh (5 shared papers)Stefani Raquel Sales Fritsch (4 shared papers)Douglas F. Nixon (11 shared papers)
Journals: Blood (11 papers)Journal of Thrombosis and Haemostasis (6 papers)Haemophilia (6 papers)Journal of Virology (3 papers)PLoS ONE (3 papers)
Partner nations: United States Sweden United Kingdom

In The Last Decade

Gerald E. Spotts

46 papers receiving 2.4k citations

Gerald E. Spotts's Hit Papers

align trajectories log scale

Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection 2008 · 639 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2008 The Journal of Experimental Medicine

Peers

Countries citing papers authored by Gerald E. Spotts

Since Specialization

Citations

This map shows the geographic impact of Gerald E. Spotts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerald E. Spotts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerald E. Spotts more than expected).

Fields of papers citing papers by Gerald E. Spotts

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerald E. Spotts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerald E. Spotts. The network helps show where Gerald E. Spotts may publish in the future.

Co-authors

The 25 scholars most cited alongside Gerald E. Spotts, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gerald E. Spotts Line = papers co-authored together Gerald E. Spotts links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 46 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection The Journal of Experimental Medicine ·Richard Brad Jones, Lishomwa C. Ndhlovu, Jason D. Barbour, Prameet M. Sheth, Aashish R. Jha, Brian R. Long, Jessica C. Y. Wong, Malathy Satkunarajah Hit paper breakdown →	2008	639
2	Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A Journal of Thrombosis and Haemostasis ·P. W. COLLINS, Victor S. Blanchette, Kathelijn Fischer, S. Björkman, M. Oh, Stefani Raquel Sales Fritsch, P Schroth, Gerald E. Spotts	2008	279
3	Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight Blood ·Sven Erik Björkman, Myungshin Oh, Gerald E. Spotts, Phillip Schroth, Sandor Fritsch, Bruce M. Ewenstein, Kathleen B. Casey, Kathelijn Fischer	2011	177
4	Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens Journal of Thrombosis and Haemostasis ·Peter W. Collins, Sven Erik Björkman, Kathelijn Fischer, Victor S. Blanchette, M. Oh, P Schroth, Stefani Raquel Sales Fritsch, Kathleen B. Casey	2009	158
5	Plasma and albumin‐free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients Journal of Thrombosis and Haemostasis ·Victor S. Blanchette, Amy D. Shapiro, Ri J. Liesner, Felipe Navarro, Indira A. Warrier, P Schroth, Gerald E. Spotts, Bruce M. Ewenstein	2008	129
6	T Cell Responses to Human Endogenous Retroviruses in HIV-1 Infection PLoS Pathogens ·Keith E. Garrison, Richard Brad Jones, Duncan A. Meiklejohn, Naveed Muhammad Anwar, Lishomwa C. Ndhlovu, Joan M. Chapman, Ann L. Erickson, Ashish T. Agrawal	2007	114
7	Elevations in IL-10, TNF- α , and IFN- γ from the Earliest Point of HIV Type 1 Infection AIDS Research and Human Retroviruses ·Philip J. Norris, Brandee L. Pappalardo, Brian Custer, Gerald E. Spotts, Frederick M. Hecht, Michael Paul Busch	2006	109
8	Comparative pharmacokinetics of plasma‐ and albumin‐free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age‐related differences and implications for dose tailoring Journal of Thrombosis and Haemostasis ·Sven Erik Björkman, Victor S. Blanchette, Kathelijn Fischer, M. Oh, Gerald E. Spotts, P Schroth, Stefani Raquel Sales Fritsch, Lisa Patrone	2010	106
9	FOXP3 expressing CD127lo CD4+ T cells inversely correlate with CD38+ CD8+ T cell activation levels in primary HIV-1 infection Journal of Leukocyte Biology ·Lishomwa C. Ndhlovu, Christopher P. Loo, Gerald E. Spotts, Douglas F. Nixon, Frederick M. Hecht	2007	69
10	Human Immunodeficiency Virus Type 1 (HIV-1)-Specific CD8+TEMRACells in Early Infection Are Linked to Control of HIV-1 Viremia and Predict the Subsequent Viral Load Set Point Journal of Virology ·John W. Northfield, Christopher P. Loo, Jason D. Barbour, Gerald E. Spotts, Frederick M. Hecht, Paul Klenerman, Douglas F. Nixon, Jakob Michaëlsson	2007	69
11	Sequential Broadening of CTL Responses in Early HIV-1 Infection Is Associated with Viral Escape PLoS ONE ·Annika C. Karlsson, Astrid K. N. Iversen, Joan M. Chapman, Tulio de Oliveira, Gerald E. Spotts, Andrew James McMichael, Miles P. Davenport, Frederick M. Hecht	2007	65
12	Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic‐guided prophylaxis Haemophilia ·Leonard A. Valentino, Steven W. Pipe, P. W. COLLINS, Victor S. Blanchette, Erik E. Berntorp, Kathelijn Fischer, Bruce M. Ewenstein, M. Oh	2016	56
13	Strong Human Endogenous Retrovirus-Specific T Cell Responses Are Associated with Control of HIV-1 in Chronic Infection Journal of Virology ·Devi SenGupta, Ravi Tandon, Raphaella G. S. Vieira, Lishomwa C. Ndhlovu, Rachel Lown-Hecht, Christopher E. Ormsby, Liyen Loh, Richard Brad Jones	2011	56
14	Expansion of CD1d-restricted NKT cells in patients with primary HIV-1 infection treated with interleukin-2 Blood ·Markus Moll, Jennifer E Snyder-Cappione, Gerald E. Spotts, Frederick M. Hecht, Johan K. Sandberg, Douglas F. Nixon	2005	45
15	Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance AIDS ·Grant Nash Colfax, Eric Vittinghoff, Robert M. Grant, Paula J. Lum, Gerald E. Spotts, Frederick M. Hecht	2006	45
16	Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials Haemophilia ·Kathelijn Fischer, Peter W. Collins, Sven Erik Björkman, Victor S. Blanchette, M. Oh, Stefani Raquel Sales Fritsch, P Schroth, Gerald E. Spotts	2011	41
17	Pattern of bleeding in a large prospective cohort of haemophilia A patients: A three‐year follow‐up of the AHEAD (Advate in HaEmophilia A outcome Database) study Haemophilia ·Kate Khair, Maria Gabriella Mazzucconi, R. Parra, Elena Santagostino, Dimitrios A. Tsakiris, Cedric R.J.R. Hermans, Gerald E. Spotts, K. N. Steinitz‐Trost	2017	35
18	Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin‐free method] demonstrates efficacy, safety and low‐risk for immunogenicity in routine clinical practice Haemophilia ·Johannes Oldenburg, Jenny Goudemand, Leonard A. Valentino, Michael L. Richards, Hung S. Luu, Alexander Y. Kriukov, Hartwig Gajek, Gerald E. Spotts	2010	26
19	Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis Thrombosis and Haemostasis ·Pratima Chowdary, Kathelijn Fischer, Peter W. Collins, Amy Cotterill, Barbara A. Konkle, Victor S. Blanchette, Steven W. Pipe, Erik E. Berntorp	2020	23
20	Immune Reconstitution of CD56dimNK Cells in Individuals with Primary HIV‐1 Infection Treated with Interleukin‐2 The Journal of Infectious Diseases ·Jakob Michaëlsson, Brian R. Long, Christopher P. Loo, Lewis L. Lanier, Gerald E. Spotts, Frederick M. Hecht, Douglas F. Nixon	2007	23

About Gerald E. Spotts

Gerald E. Spotts is a scholar working on Hematology, Virology, Genetics, Immunology and Infectious Diseases, having authored 46 papers that have together received 2.5k indexed citations. Recurring topics across this work include Hemophilia Treatment and Research (29 papers), HIV Research and Treatment (13 papers), Chronic Myeloid Leukemia Treatments (9 papers), Platelet Disorders and Treatments (9 papers), Immune Cell Function and Interaction (8 papers), T-cell and B-cell Immunology (5 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers) and Blood Coagulation and Thrombosis Mechanisms (4 papers). The work is most often cited by research in Virology (486 citations), Hematology (1.1k citations), Immunology (839 citations), Genetics (200 citations) and Oncology (223 citations). Gerald E. Spotts has collaborated with scholars based in United States, Sweden and United Kingdom. Frequent co-authors include Bruce M. Ewenstein, Victor S. Blanchette, Kathelijn Fischer, Frederick M. Hecht, P Schroth, M. Oh, Stefani Raquel Sales Fritsch, Douglas F. Nixon, Peter W. Collins and Sven Erik Björkman. Their work appears in journals such as Blood, Journal of Thrombosis and Haemostasis, Haemophilia, Journal of Virology and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Gerald E. Spotts

Impact in

Papers in i

In The Last Decade

Gerald E. Spotts

Gerald E. Spotts's Hit Papers

Peers

Countries citing papers authored by Gerald E. Spotts

Fields of papers citing papers by Gerald E. Spotts

All Works

About Gerald E. Spotts

Explore authors with similar magnitude of impact

Papers in